Register

Podcast Details

Biogen Idec Phase III Clinical Trial "Empower"

ALS TDI Podcasts
An interview with Dr. Doug Kerr on the design and purpose of the dexpramipexole trial
 
Date: 05/17/2011
Author: Robert A. Goldstein
 
Doug Kerr, M.D., Ph.D. is a Medical Director in Experimental Neurology at Biogen Idec and the lead on their newly launched Phase III clinical trial in ALS. During this 20 minute interview, Kerr walks us through how Biogen Idec got to this point, how it designed the trial and what patients can expect from the trial in the clinic. The trial began enrolling in April 2011 and has a goal of 804 patients enrolled through 83 locations in North America, Europe and Australia.
 
Duration: 00:20:06
Size: 2413 kb
 
ListenListen
podcast on iTues iTunes
Subscribe Subscribe
 

Find this useful?
Help us fund more science: